Intradiscal glycerol or bupivacaine in the treatment of low back pain.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 9248588.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A total of 15 patients suffering from chronic low back pain were treated with an intradiscal injection of either 1 ml of 50% glycerol or 2 ml of 0.5% bupivacaine. Most (60%) of the patients had previously undergone spinal surgery for lumbar disc herniation or spinal stenosis and 73% showed clinical signs and symptoms of segmental instability of the lumbar spine. According to self-evaluation questionnaires, immediate response to both treatments was mainly good. Of the 9 patients who received glycerol, 56% showed subjective improvement on the first day after the injection and after two weeks, 45% of the patients still felt improvement. After one month, however, the pain had reappeared in all except one (11%) patient. The corresponding numbers for the 6 with bupivacaine treated patients were 83%, 67%, and 17%. Based on the very short duration of response to the treatment, we did not find intradiscal injections with these agents to be cost-effective. In our department, this therapeutic approach is no longer employed in patients with chronic discogenic pain.
Medical subject headings
- Anesthetics, Local
- Bupivacaine
- Cryoprotective Agents
- Glycerol
- Intervertebral Disc Displacement
- Low Back Pain